Avalo Therapeutics, Inc. (AVTX) company profile
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
About Avalo Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology firm that develops therapies targeting interleukin-1β for immune-mediated inflammatory diseases. Its primary product candidate is abdakibart, a humanized monoclonal antibody designed to block interleukin-1β and inhibit downstream inflammatory pathways. The candidate targets adults with moderate to severe hidradenitis suppurativa, a debilitating chronic skin condition. The firm also maintains legacy programs across other inflammatory and mitochondrial disorders. As its candidates remain in clinical evaluation without regulatory approvals, the company currently engages clinical study participants, with future customers comprising patients who suffer from underserved inflammatory diseases.
The enterprise conducts clinical operations across thirteen countries, including the United States, Canada, France, Germany, Italy, Spain, Bulgaria, the Czech Republic, Greece, Poland, Australia, Turkey, and Slovakia. Its primary Phase 2 trial encompasses approximately 250 adult participants. The business owns no manufacturing facilities, relying on external contract development and manufacturing organizations to produce its biologic supplies. The provided text does not state the location of the corporate headquarters.
Summary of the business section of Avalo Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Avalo Therapeutics, Inc.
- Headquarters
- Wayne, PA
- Address
- 1500 Liberty Ridge Drive, Suite 321 19087
- Phone
- (410) 522-8707
- Website
- avalotx.com
- Employees
- 23, Dec 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Jericho, New York
Stock & identifiers
- Ticker
- AVTX
- Former tickers
- CERC until Aug 26, 2021
- Exchange
- Nasdaq
- IPO date
- Oct 15, 2015
- Shares outstanding
- 54M, Aug 3, 2026
- Public float
- $53.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-240 reverse, Dec 29, 2023; 1-for-12 reverse, Jul 8, 2022
- SEC CIK
- 1534120
- CUSIP
- 05338F306
- ISIN
- US05338F3064
- FIGI
- BBG001QHW0Y8
- Share class FIGI
- BBG001V1GPQ9
- LEI
- 549300GPK6FPJ3X8SZ39
- EIN
- 45-0705648
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Garry Arthur Neil | Chief Executive Officer, Director | 190,314 |
| Christopher Ryan Sullivan | Chief Financial Officer | 39,900 |
| Mittie Doyle | Chief Medical Officer | 51,776 |
| Jennifer Riley | Chief Strategy Officer | 37,041 |
| Paul Varki | Chief Legal Officer | 32,576 |
| Taylor Boyd | Chief Business Officer | – |
| Rita Jain | Director | – |
| Ron M. Philip | Director | – |
| Kevin Robert Lind | Director | – |
| Samantha Truex | Director | 6,333 |
| Gilla Kaplan | Director | 6,333 |
| Aaron Kantoff | Director | 6,333 |
| Michael Thomas Heffernan | Director | – |
| Mitchell Chan | Director | 3,166 |
| Jonathan Goldman | Director | 3,166 |
| June Sherie Almenoff | Director | 4,167 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Garry Neil M.D. | $3.81M | $12.30M | $2.50M | $2 | – |
| FY2025 Michael Cola | $0 | $0 | $2.50M | $2 | – |
| FY2024 Garry Neil M.D. | $7.21M | $5.39M | $2.98M | $1 | – |
| FY2024 Michael Cola | $0 | $0 | $2.98M | $1 | – |
| FY2023 Garry Neil M.D. | $1.08M | $141.73K | $607.65K | $1 | – |
| FY2023 Michael Cola | $320.41K | $320.41K | $607.65K | $1 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Garry Neil Chief Executive Officer, President and principal executive officer | $590.00K | $2.73M | $474.95K | $10.33K | $3.81M | -47% |
| Taylor Boyd Chief Business Officer | $116.25K | $3.05M | $52.08K | $1.94K | $3.22M | – |
| Mittie Doyle Chief Medical Officer | $512.50K | $1.03M | $229.60K | $8.03K | $1.78M | -41% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 15, 2015
- Offer price
- $6.50
- Securities offered
- 4,000,000
- Gross proceeds
- $26.00M
- Exchange
- Nasdaq
- First trading day
- Oct 14, 2015
- First-day close
- $6.500.0%
- Lock-up ends (est.)
- Apr 11, 2016
“Each of the Class A Warrants is exercisable on or before October 20, 2018 to purchase one share of our common stock at an exercise price of $4.55 per share, based on the initial public offering price of $6.50 per unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2024, we had twenty-three employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?